Prostate Cancer: Later Stage Treatment

Treatment for advanced prostate disease has improved dramatically over the last 10 years and continues to improve. In this series, SurvivorNet doctors help compare the pros and cons of each treatment.

Later Stage Treatment: New Treatment Developments

SEE MORE   

  • There are several new drugs and treatment options available for those facing advanced stage prostate cancer.
  • Two PARP inhibitors are currently FDA-approved: Lynparza (olaparib) and Rubraca (rucaparib).
  • Two newer androgen deprivation therapies include: Xtandi (enzalutamide) Erleada (apalutamide).

Later Stage Treatment: New Treatment Developments

  • There are several new drugs and treatment options available for those facing advanced stage prostate cancer.
  • Two PARP inhibitors are currently FDA-approved: Lynparza (olaparib) and Rubraca (rucaparib).
  • Two newer androgen deprivation therapies include: Xtandi (enzalutamide) Erleada (apalutamide).
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.